novo nordisk semaglutide oral says works in diabetic kids Novo Nordisk launched an oral

PMID: 37821008

It demonstrated that GLP-1 RAs can modulate intestinal farnesoid X receptor (FXR) signaling to improve joint health [168]

Definitive evidence regarding the efficacy of semaglutide in such populations is anticipated from the ongoing SOUL trial (NCT03914326), which is evaluating MACE prevention over 5 years in patients with T2D and established CVD or CKD [61]

placebo over 52 weeks Efficacy observed both as monotherapy or combined with antifibrotics Well-tolerated, reduced death risk, though did not show statistically significant survival benefit Why it matters: Anti-inflammatory mechanism differentiates JASCAYD from existing antifibrotics (nintedanib, pirfenidone) Reinforces Boehringers leadership in respiratory innovation and re-energizes IPF R&D after years of limited breakthroughs Follow our page for more such updates: News Source: #FDAApproval #IPF #PulmonaryFibrosis #Respiratory #RespiratoryMedicine #DrugDevelopment #BoehringerIngelheim #Ofev #Esbriet #PharmaInnovation To view or add a comment, sign in FDA Approves Boehringer Ingelheims JASCAYD (nerandomilast) for IPF The U.S

The most common adverse reactions of Semaglutide are: Swelling / redness /itching at the injection site, tiredness , nausea , vomiting , diarrhea

There were no increased risks of severe hypoglycaemia, retinopathy, or pancreatic events